



EUROPEAN  
HEMATOLOGY  
ASSOCIATION

### Focus:

- Clinical features and laboratory evaluation of congenital and acquired platelet and clotting factors abnormalities.
- Assessment of commonly acquired disorders of hemostasis leading to bleeding or thrombosis and recognized features of hereditary platelet disorders.
- Updates in cancer-associated thrombosis: risk assessment, prevention, and anticoagulant therapy.
- Evaluating antibody-mediated prothrombotic disorders.
- Discussions on the advancements in venous thromboembolism treatment and features of newer anticoagulant drugs.
- Identifying gaps in thrombotic and bleeding disorders to be incorporated into future research programs.

### Why attend?

Review the latest findings and discuss challenging patient cases with experts during interactive sessions. A voting box system will be used for self-assessment and a round table session will allow discussion with patient organizations. In addition, a welcome reception offers you the opportunity to network with the faculty and delegates.

### Target group:

The meeting is aimed towards specialists in hematology (clinicians, researchers, biologists, and students) interested in the field of thrombosis and hemostasis, or directly involved in clinical management of bleeding and thrombotic diseases.

**Meeting Language:** English

**For registration, please go to [www.ehaweb.org](http://www.ehaweb.org)**

### EHA Executive Office

Koninginnegracht 12b | 2514 AA The Hague | The Netherlands

Tel: +31 (0)70 3020 099

[www.ehaweb.org](http://www.ehaweb.org)



EHA-SWG SCIENTIFIC MEETING

REGISTER  
NOW!  
[ehaweb.org](http://ehaweb.org)

# Hemostasis imbalance: Critical issues and Therapeutic approaches

**Dates:** September 18-20, 2015

**Location:** Barcelona, Spain

### Organized by:

EHA Scientific Working Group  
(SWG) Bleeding and thrombosis  
in onco-hematology & SWG  
Thrombocytopenias and platelet  
function disorders

### Chairs:

A Falanga & C Balduini

### Topics:

- Management of acquired coagulopathies with massive hemorrhages: The role of plasma, platelets, and coagulation factor concentrates
- Clinical utility of global coagulation assays
- Latest developments in the thrombotic risk assessment
- Current and future treatments for platelet disorders
- Plenary lectures on platelets in hemostasis and thrombosis & new insights into modulation of thrombin formation
- Bleeding risk and emergencies in subjects with platelet function disorders
- Interactive sessions on facing a thrombophilic state & bleeding risk and emergencies in thrombocytopenic subjects
- Exchange of views on the use and limitations of new oral anticoagulants for VTE



Early registration deadline: August 20, 2015. More info [ehaweb.org](http://ehaweb.org)

## EHA-SWG SCIENTIFIC MEETING

# Hemostasis imbalance: Critical issues and Therapeutic approaches

September 18-20, 2015, Barcelona, Spain

### Day 1, Friday

Time	Title	Speaker
13:00-14:00	<b>Registration</b>	
14:00-14:15	Welcome & Introductory Remarks	C Balduini & A Falanga
14:15-14:45	PLENARY LECTURE: New insights into modulation of thrombin formation	H Ten Cate
14:45-16:15	<b>Management of acquired coagulopathies with massive hemorrhages: The role of plasma, platelets, and coagulation factor concentrates</b>	Chair: S Eichinger
14:45-15:15	Management of the coagulopathy of acute leukemias	A Falanga
15:15-15:45	Management of the acquired coagulation defects	I Elalamy
15:45-16:15	Management of anticoagulation overdosing	S Eichinger
16:15-16:45	<b>Coffee break</b>	
16:45-18:15	<b>Clinical utility of global coagulation assays</b>	Chair: M Marchetti
16:45-17:15	Goal directed therapy for venous and arterial thrombosis	P Simioni
17:15-17:45	Global hemostasis assays in the management of the coagulopathy of trauma	B de Laat
17:45-18:15	The predictive role of thrombin generation assay in cancer-associated VTE	M Marchetti
18:15-19:30	<b>Welcome Reception</b>	

### Day 2, Saturday

Time	Title	Speaker
09:00-10:30	<b>Latest developments in the thrombotic risk assessment</b>	Chair: A Falanga
09:00-09:30	Thrombosis: A major contributor to global disease burden in cancer patients	N Kuderer
09:30-10:00	The risk assessment of VTE in patients with cancer	I Pabinger
10:00-10:30	Current and future anticoagulant treatments in patients with cancer and thrombosis	AK Kakkar
10:30-11:00	<b>Coffee break</b>	
11:00-12:30	<b>INTERACTIVE SESSION 1: Facing a thrombophilic state</b>	Chair: T Barbui
11:00-11:30	Prevention of thrombotic complications in myeloproliferative neoplasms	T Barbui
11:30-12:00	Anticoagulant use during pregnancy	R Bauersachs

12:00-12:30	Prevention of VTE in patients with multiple myeloma	F Leebeek
12:30-14:00	<b>Lunch</b>	
14:00-15:30	<b>Current and future treatments for platelet disorders - 1</b>	Chair: F Rodeghiero
14:00-14:30	Immune thrombocytopenia	F Rodeghiero
14:30-15:00	Neonatal alloimmune thrombocytopenia	J Kjeldsen Kragh
15:00-15:30	Heparin induced thrombocytopenia	A Greinacher
15:30-16:00	<b>Coffee break</b>	
16:00-17:00	<b>Current and future treatments for platelet disorders - 2</b>	Chair: MA Scully
16:00-16:30	Current and future treatments for TTP and HUS	MA Scully
16:30-17:00	Current and future treatments for inherited thrombocytopenias	A Pecci
17:00-18:30	<b>Evolving use and limitations of new oral anticoagulants for VTE</b>	Chair: H Ten Cate
	Round table with representatives of patient organizations and pharmaceutical company	
17:00-17:10	Introduction	H ten Cate
17:10-17:25	International Self-Monitoring Association of oral Anticoagulated Patients (ISMAAP)	C Schaefer
17:25-17:40	Dutch Heart Foundation	H van Laarhoven
17:40-17:55	Development of one of the new oral anticoagulants	tbc
17:55-18:30	Discussion with the speakers and the audience	All

### Day 3, Sunday

Time	Title	Speaker
09:00-09:30	PLENARY LECTURE: Platelets in hemostasis and thrombosis	C Gachet
09:30-11:00	<b>Bleeding risk and emergencies in subjects with platelet function disorders</b>	Chair: A Greinacher
09:30-10:00	Clinical management of patients with disorders of platelet function	M Cattaneo
10:00-10:30	Laboratory characterization of disorders of platelet function	P Gresele
10:30-11:00	Peri-interventional management of patients receiving anti-platelet therapy	A Greinacher
11:00-11:30	<b>Coffee break</b>	
11:30-13:00	<b>INTERACTIVE SESSION 2: Bleeding risk and emergencies in thrombocytopenic subjects</b>	Chair: C Balduini
11:30-12:00	Which is the "safe" level of platelet count?	P Noris
12:00-12:30	Are platelet transfusions effective in preventing bleeding in thrombocytopenic patients?	S Stanworth
12:30-13:00	Emergency treatment of hemorrhages in ITP	M Michel
13:00-13:10	Concluding Remarks	A Falanga, C Balduini
13:10-14:00	<b>Lunch and Departures</b>	